0001225208-20-007336.txt : 20200508
0001225208-20-007336.hdr.sgml : 20200508
20200508191738
ACCESSION NUMBER: 0001225208-20-007336
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200507
FILED AS OF DATE: 20200508
DATE AS OF CHANGE: 20200508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUSSALLEM MICHAEL A
CENTRAL INDEX KEY: 0001204551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 20862213
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES CORP
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0306
4
2020-05-07
0001099800
Edwards Lifesciences Corp
EW
0001204551
MUSSALLEM MICHAEL A
ONE EDWARDS WAY
IRVINE
CA
92614
1
1
Chairman & CEO
Common Stock
2020-05-07
4
A
0
7075.0000
0.0000
A
44200.8200
D
Common Stock
2020-05-08
4
M
0
32850.0000
35.7850
A
77050.8200
D
Common Stock
2020-05-08
4
S
0
300.0000
221.5800
D
76750.8200
D
Common Stock
2020-05-08
4
S
0
2900.0000
218.5400
D
73850.8200
D
Common Stock
2020-05-08
4
S
0
5548.0000
217.7800
D
68302.8200
D
Common Stock
2020-05-08
4
S
0
6604.0000
220.8600
D
61698.8200
D
Common Stock
2020-05-08
4
S
0
7498.0000
220.1000
D
54200.8200
D
Common Stock
2020-05-08
5
G
0
10000.0000
0.0000
D
44200.8200
D
Common Stock
2020-05-08
5
G
0
10000.0000
0.0000
A
891194.0000
I
By Living Trust
Common Stock
123918.8025
I
401(k)
Employee Stock Option (Right to Acquire)
218.0400
2020-05-07
4
A
0
70700.0000
0.0000
A
2020-06-07
2027-05-06
Common Stock
70700.0000
70700.0000
D
Performance Rights
2020-05-07
4
A
0
8825.0000
0.0000
A
2023-05-07
2027-05-06
Common Stock
8825.0000
8825.0000
D
Employee Stock Option (Right to Acquire)
35.7850
2020-05-08
4
M
0
32850.0000
0.0000
D
2013-06-14
2020-05-13
Common Stock
32850.0000
0.0000
D
These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.
This transaction was executed in multiple trades at prices ranging from $221.46 to $221.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $218.24 to $219.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $217.22 to $218.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $220.43 to $221.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $219.43 to $220.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Shares represented on the most recent statement of Issuer's 401(k) Plan Administrator.
These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2020-05-08